AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15613405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose testosterone administration
Number of subjects: 18
Study 15613405 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 18
Study 12186604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50-micro g tablet once daily)
Number of subjects: 300
Study 12186604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 12186604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 300
Study 10452638 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg/d)
Number of subjects: 198
Study 10452638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 7889438 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 19
Study 7889438 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 2357869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 10 mg
Number of subjects: 0
Study 2357869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 25 mg
Number of subjects: 0
Study 2357869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 10 mg and 25 mg
Number of subjects: 0
Study 2357869 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 0
Study 2357869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 5 mg
Number of subjects: 0
Study 2357869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 695520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine (300 mg on day 1, 200 mg on day 2, 100 mg on days 3 and 4; contacts received 100 mg for 7 to 10 days)
Number of subjects: 146
Study 695520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine (prophylactic use)
Number of subjects: 146
Study 695520 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic drugs (control group)
Number of subjects: 146
Study 30630815 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg and 75 mg on two following days)
Number of subjects: 11
Study 30630815 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg BID for 5 days)
Number of subjects: 11
Study 30630815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study 29388926 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized therapy including robotized mechanotherapy, stabilography, neuro-muscular stimulation, kinesiotherapy, physical therapy, ergotherapy, massage, etc.
Number of subjects: 68
Study 29388926 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 68
Study 26597741 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 60 mg/d
Number of subjects: 174
Study 26597741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 23581554 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal risk factors (maternal gestational smoking and drug use, early labor, low birth weight, infant breathing problems)
Number of subjects: 719
Study 23581554 — intervention group
Group type: COMPARATOR
Intervention: Control for family socioeconomic status (SES) and maternal symptoms of ADHD and depression
Number of subjects: 719
Study 23581554 — intervention group
Group type: COMPARATOR
Intervention: Control for the number of child comorbidities plus SES and maternal symptoms
Number of subjects: 719
Study 21425567 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Huopo Xialing Decoction (HXD)
Number of subjects: 50
Study 21425567 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (Control)
Number of subjects: 50
Study 19767074 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (30mg/d for 14 days)
Number of subjects: 73
Study 19767074 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized inhaled fluticasone dose
Number of subjects: 73
Study 19767074 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of control
Number of subjects: 73
Study 19767074 — intervention group
Group type: COMPARATOR
Intervention: Predicted values from Olin et al
Number of subjects: 73
Study 19767074 — intervention group
Group type: COMPARATOR
Intervention: Predicted values from Travers et al
Number of subjects: 73
Study 19767074 — intervention group
Group type: COMPARATOR
Intervention: Predicted values from Dressel et al
Number of subjects: 73
Study 17363859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy group (8 sessions)
Number of subjects: 20
Study 17363859 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 20
Study 14626333 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based delivery of inhaled corticosteroids (ICS)
Number of subjects: 50
Study 14626333 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based delivery of inhaled corticosteroids (ICS)
Number of subjects: 50
Study 14626333 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based delivery of inhaled corticosteroids (ICS) with school-based asthma education
Number of subjects: 50
Study 14626333 — intervention group
Group type: COMPARATOR
Intervention: Community standard of care (control group)
Number of subjects: 50
Study 14626333 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (combined)
Number of subjects: 50
Study 10768961 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 106
Study 10768961 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal A/C polysaccharide vaccine
Number of subjects: 106
Study 9494585 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 23
Study 9494585 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 23
Study 8443036 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (50 nmol) applied to the human nasal mucosa
Number of subjects: 0
Study 8443036 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied to the contralateral nostril
Number of subjects: 0
Study 3538945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg three times daily)
Number of subjects: 82
Study 3538945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 3538945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (after initial treatment with placebo)
Number of subjects: 82
Study 3538945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after initial treatment with ketanserin)
Number of subjects: 82
Study 3538945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in crossover treatment)
Number of subjects: 82
Study 3538945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (in crossover treatment)
Number of subjects: 82
Study 31347430 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 to 200 mg plus cilostazol 200 mg (dual group)
Number of subjects: 1201
Study 31347430 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 to 200 mg (aspirin group)
Number of subjects: 1201
Study 30205371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L peripheral intravenous nutrition, 700 kcal
Number of subjects: 80
Study 30205371 — intervention group
Group type: COMPARATOR
Intervention: 1 L isotonic electrolyte solution
Number of subjects: 80
Study 27044959 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel multidimensional intervention aimed at improving patient-provider communication.
Number of subjects: 300
Study 27044959 — intervention group
Group type: COMPARATOR
Intervention: Existing intervention focused on changing patients' behaviors.
Number of subjects: 300
Study 24337154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion (48 h, 30 ml/h)
Number of subjects: 12
Study 22134012 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO I (Ethanol 80% vol/vol)
Number of subjects: 0
Study 22134012 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO II (Isopropanol 75% vol/vol)
Number of subjects: 0
Study 22134012 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO I and WHO II with increased alcohol concentrations (80% wt/wt and 75% wt/wt)
Number of subjects: 0
Study 22134012 — intervention group
Group type: COMPARATOR
Intervention: Reference procedure 'R' (2 × 3 mL 60% vol/vol isopropanol for 2 × 30 seconds)
Number of subjects: 0
Study 19832918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (H(2)O(2); 0.013% H(2)O(2)/0.004% glycerol)
Number of subjects: 40
Study 19832918 — intervention group
Group type: COMPARATOR
Intervention: Placebo without H(2)O(2)
Number of subjects: 40
Study 17197302 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical technique
Number of subjects: 80
Study 17197302 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical approach
Number of subjects: 80
Study 15860854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m(2)) plus docetaxel (75 mg/m(2)) IV every 3 weeks (AD)
Number of subjects: 363
Study 15860854 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) IV every 3 weeks (AC)
Number of subjects: 363
Study 11914161 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended structured recall and management system involving patients and clinical management prompts based on evidence-based guidelines.
Number of subjects: 61
Study 11914161 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned but implied).
Number of subjects: 61
Study 10190766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous-glycine-sulfate (200 mg elemental iron daily)
Number of subjects: 0
Study 10190766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10190766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Iron and Placebo)
Number of subjects: 0
Study 7787913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink tape
Number of subjects: 103
Study 7787913 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear tape
Number of subjects: 103
Study 7787913 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterfly tape
Number of subjects: 103
Study 7787913 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal tubes
Number of subjects: 103
Study 7787913 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sump tubes
Number of subjects: 103
Study 2085988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT, 3 g)
Number of subjects: 36
Study 2085988 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX, 960 mg, 3 times daily)
Number of subjects: 36
Study 2085988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT)
Number of subjects: 36
Study 2085988 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX)
Number of subjects: 36
Study 479908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined histamine H1 and H2 antagonist treatment
Number of subjects: 15
Study 479908 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study 31371364 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided glucose management protocol
Number of subjects: 66
Study 31371364 — intervention group
Group type: COMPARATOR
Intervention: Routine glycemic monitoring approach
Number of subjects: 66
Study 28856906 — intervention group
Group type: EXPERIMENTAL
Intervention: P169 supplementation at a rate of 1×10^11 cfu/head/d
Number of subjects: 7
Study 28856906 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n=3)
Number of subjects: 7
Study 28856906 — intervention group
Group type: EXPERIMENTAL
Intervention: P169 supplementation
Number of subjects: 7
Study 24838423 — intervention group
Group type: EXPERIMENTAL
Intervention: 23G needle
Number of subjects: 119
Study 24838423 — intervention group
Group type: COMPARATOR
Intervention: 25G needle
Number of subjects: 119
Study 24173486 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard illustrated discharge cards
Number of subjects: 228
Study 24173486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cards)
Number of subjects: 228
Study 21371381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 48
Study 21371381 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 48
Study 19521070 — intervention group
Group type: EXPERIMENTAL
Intervention: paricalcitol 1 micro/day
Number of subjects: 281
Study 19521070 — intervention group
Group type: EXPERIMENTAL
Intervention: paricalcitol 2 microg/day
Number of subjects: 281
Study 19521070 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 281
Study 17910230 — intervention group
Group type: EXPERIMENTAL
Intervention: SE Bond Cuspal coverage restorations
Number of subjects: 72
Study 17910230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT Cuspal coverage restorations
Number of subjects: 72
Study 17910230 — intervention group
Group type: COMPARATOR
Intervention: Cuspal coverage restorations (SE and PB)
Number of subjects: 72
Study 17910230 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased thickness in bonding agent in Class I restorations
Number of subjects: 72
Study 17910230 — intervention group
Group type: COMPARATOR
Intervention: Bulk‐filled direct resin composite Cuspal coverage restorations
Number of subjects: 72
Study 17910230 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal adaptation of Cuspal coverage SE Bond/Clearfil AP‐X restorations
Number of subjects: 72
Study 15061249 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 552
Study 15061249 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 552
Study 11159234 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.01 microg. kg(‐1). min(‐1) to 0.17 microg. kg(‐1). min(‐1))
Number of subjects: 20
Study 11159234 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 9491827 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine-pseudoephedrine (L + PS)
Number of subjects: 40
Study 9491827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 40
Study 7936257 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol for treatment of acute stroke including a critical path for nursing care, an algorithm for emergency department care, and suggested admission orders for physicians.
Number of subjects: 390
Study 7936257 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol for treatment of acute stroke
Number of subjects: 390
Study 6099707 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous cyclophosphamide
Number of subjects: 0
Study 31248746 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including an online tool, meet-and-greet sessions, and research assistants.
Number of subjects: 5255
Study 30369307 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105
Study 30369307 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 27452936 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 85
Study 27452936 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 85
Study 24528934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (Ozurdex)
Number of subjects: 50
Study 24528934 — intervention group
Group type: COMPARATOR
Intervention: Macular grid laser
Number of subjects: 50
Study 22324949 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg once daily for the first month and twice daily for the next 2 months with diclofenac sodium 75 mg once daily
Number of subjects: 74
Study 22324949 — intervention group
Group type: COMPARATOR
Intervention: Placebo with diclofenac sodium 75 mg once daily
Number of subjects: 74
Study 19946814 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization at the patient level
Number of subjects: 0
Study 19946814 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of measurements
Number of subjects: 0
Study 19946814 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding a covariate
Number of subjects: 0
Study 19946814 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% drop-out rate
Number of subjects: 0
Study 19946814 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sample sizes
Number of subjects: 0
Study 19946814 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger sample sizes
Number of subjects: 0
Study 17091024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential estradiol‐norethisterone acetate regimen for 3 months
Number of subjects: 100
Study 17091024 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued HT for 6 months
Number of subjects: 100
Study 17091024 — intervention group
Group type: EXPERIMENTAL
Intervention: HT
Number of subjects: 100
Study 17091024 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 100
Study 17683453 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual speech perception
Number of subjects: 37
Study 17683453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipreading ability
Number of subjects: 37
Study 17683453 — intervention group
Group type: COMPARATOR
Intervention: Audiovisual condition
Number of subjects: 37
Study 15000640 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental placement technique using Single Bond + Filtek Z250
Number of subjects: 6
Study 15000640 — intervention group
Group type: COMPARATOR
Intervention: Bulk placement technique using Single Bond + Filtek P60
Number of subjects: 6
Study 10885414 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoSet (autoadjusting nasal CPAP)
Number of subjects: 10
Study 10885414 — intervention group
Group type: COMPARATOR
Intervention: Conventional nasal CPAP (manual mode)
Number of subjects: 10
Study 8781301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (VS) 50 mg twice daily orally for 4 weeks
Number of subjects: 8
Study 8781301 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 8
Study 1352496 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 53
Study 1352496 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nitrendipine
Number of subjects: 53
Study 6496393 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein diet (55% beef protein)
Number of subjects: 8
Study 6496393 — intervention group
Group type: COMPARATOR
Intervention: Plant protein diet
Number of subjects: 8
Study 31563148 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% sodium hypochlorite
Number of subjects: 308
Study 31563148 — intervention group
Group type: COMPARATOR
Intervention: 5.25% sodium hypochlorite
Number of subjects: 308
Study 31601569 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18K322A with induction chemotherapy
Number of subjects: 42
Study 28217883 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 0
Study 28217883 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 0
Study 26177630 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CTG + PRF
Number of subjects: 40
Study 26177630 — intervention group
Group type: COMPARATOR
Intervention: CAF + CTG
Number of subjects: 40
Study 23706094 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention including educational weight loss workbook, pedometer, elastic Thera-bands® for strength training, and behavioral telephone-based coaching.
Number of subjects: 0
Study 23706094 — intervention group
Group type: COMPARATOR
Intervention: Standard care including educational weight loss workbook and pedometer for self-monitoring of physical activity.
Number of subjects: 0
Study 21737832 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied during arthroscopic rotator cuff repair
Number of subjects: 42
Study 21737832 — intervention group
Group type: COMPARATOR
Intervention: Conventional repair (without PRP)
Number of subjects: 42
Study 21737832 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP group
Number of subjects: 42
Study 21737832 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of PRP vs conventional repair
Number of subjects: 42
Study 19491556 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release guaifenesin/pseudoephedrine hydrochloride
Number of subjects: 0
Study 19491556 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 0
Study 16770976 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) injections plus standard clinical care
Number of subjects: 138
Study 16770976 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care alone
Number of subjects: 138
Study 16770976 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded LMWH group
Number of subjects: 138
Study 16770976 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded LMWH group
Number of subjects: 138
Study 16770976 — intervention group
Group type: COMPARATOR
Intervention: Blinded placebo arm
Number of subjects: 138
Study 16770976 — intervention group
Group type: COMPARATOR
Intervention: Standard care arm
Number of subjects: 138
Study 16770976 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH arms
Number of subjects: 138
Study 16770976 — intervention group
Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 138
Study 14763475 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 30
Study 14763475 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 30
Study 11480653 — intervention group
Group type: EXPERIMENTAL
Intervention: Titratable oral appliance in mandibular position MAX67
Number of subjects: 10
Study 11480653 — intervention group
Group type: EXPERIMENTAL
Intervention: Titratable oral appliance in mandibular position MAX
Number of subjects: 10
Study 11480653 — intervention group
Group type: COMPARATOR
Intervention: Titratable oral appliance in mandibular position RP
Number of subjects: 10
Study 9428829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg/day for 14 days followed by 76 days of elemental calcium 500 mg/day)
Number of subjects: 193
Study 9428829 — intervention group
Group type: COMPARATOR
Intervention: Calcium only (placebo)
Number of subjects: 193